Here, we present the first case showing the anti‐tumor efficacy of afatinib and the second case showing the anti‐tumor efficacy of osimertinib in a patient with EGFR L861R‐positive lung adenocarcinoma. The gene discussed is EGFR; the disease is lung adenocarcinoma.